reports
BioAtla to Participate in the Citizens JMP Life Sciences Conference
BioAtla to Participate in the Citizens JMP Life Sciences Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024. Format: Fireside chat and scheduled one-on-one investor meetingsDate: Monday, ...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals ma...
Heritage Insurance Holdings Inc: 3 directors
A director at Heritage Insurance Holdings Inc bought 10,000 shares at 8.190USD and the significance rating of the trade was 36/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
HUBB HUBBELL INCORPORATED CLASS B
ECL ECOLAB INC.
CTRN CITI TRENDS INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
EFR ENERGY FUELS
HTLD HEARTLAND EXPRESS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
TDUP THREDUP INC.
TBBK THE BANCORP
VPV INC.
MEGI INVESCO PA VALUE MUNI INC TST
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
ASGI NUVEEN CORE PLUS IMPACT FD
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
DIEBOLD NIXDORF INCORPORATED
Avid Bioservices to Participate at Upcoming Investor Conferences
Avid Bioservices to Participate at Upcoming Investor Conferences TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming investor conferences. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the RBC Capital Markets 20...
Ocular Therapeutix™ Reports First Quarter 2024 Results
Ocular Therapeutix™ Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed t...
BioAtla to Announce First Quarter 2024 Financial Results and Provide B...
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024 SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights. Conference Call and Webcas...
- Jonathan Moreland
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
LTRX LANTRONIX INC.
HXL HEXCEL CORPORATION
HOO HERBALIFE NUTRITION LTD.
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
EAF GRAFTECH INTERNATIONAL
GH GUARDANT HEALTH
DNA GINKGO BIOWORKS HOLDINGS
TBBK INC.
RXO_w THE BANCORP
VSTS_w INC.
CFFI RXO INC
RENT VESTIS CORPORATION
C&F FINANCIAL CORPORATION
RENT THE RUNWAY INC
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programming & Data Oper...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results an...
BioAtla Announces FDA Clearance of Investigational New Drug Applicatio...
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for ...
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Conference Fireside Chat Date:...
- Wedbush Research
UDR UDR INC.
TXRH TEXAS ROADHOUSE INC.
PFPT PROOFPOINT INC.
PANW PALO ALTO NETWORKS INC.
MIME MIMECAST LIMITED
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
FTNT FORTINET INC.
FATE FATE THERAPEUTICS INC
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
DECK DECKERS OUTDOOR CORPORATION
CYBR CYBERARK SOFTWARE LTD.
CPT CAMDEN PROPERTY TRUST
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
AVB AVALONBAY COMMUNITIES INC.
ABR ARBOR REALTY TRUST INC.
BJRI BJ'S RESTAURANTS INC.
DRI DARDEN RESTAURANTS INC.
OKTA OKTA INC. CLASS A
VICI VICI PROPERTIES INC
SAIL SAILPOINT TECHNOLOGIES
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ZS ZSCALER INC.
DDOG DATADOG INC CLASS A
PLTR PALANTIR TECHNOLOGIES
S SENTINELONE INC
- David Carlson
- David Nierengarten
- Dennis Pak
- Martin Fan
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for...
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripote...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9,...
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, announced multiple presentations at the Ophthalmology...
Chart Industries Reports First Quarter 2024 Financial Results
Chart Industries Reports First Quarter 2024 Financial Results ATLANTA, May 03, 2024 (GLOBE NEWSWIRE) -- Chart Industries, Inc. (NYSE: GTLS) (“Chart”) today reported results for the first quarter ended March 31, 2024. Results shown are from continuing operations. When referring to any comparative period, all metrics are pro forma for continuing operations of the combined business of Chart and Howden, unless noted otherwise. First quarter 2024 highlights compared to first quarter 2023, pro forma: Orders, backlog, sales, reported and adjusted gross margin, reported and adjusted op...
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
ORI OLD REPUBLIC INTERNATIONAL CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
CVS CVS HEALTH CORPORATION
SWKS SKYWORKS SOLUTIONS INC.
CECE CECO ENVIRONMENTAL CORP.
CPZ CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
TBBK THE BANCORP
CFFI INC.
C&F FINANCIAL CORPORATION
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T ...
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it will host a virtual Key Opinion Leader and Analyst-Investor Day on Monday, May 6, 2024 from 11:30 AM to 1:30 PM ET. To register, The program will cover the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.